Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - DNA/RNA Synthesis - SR 11302

SR 11302

CAS No. 160162-42-5

SR 11302( —— )

Catalog No. M27717 CAS No. 160162-42-5

SR 11302 is an inhibitor of activator protein-1 (AP-1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 115 Get Quote
10MG 178 Get Quote
25MG 357 Get Quote
50MG 557 Get Quote
100MG 795 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    SR 11302
  • Note
    Research use only, not for human use.
  • Brief Description
    SR 11302 is an inhibitor of activator protein-1 (AP-1).
  • Description
    SR 11302 is an inhibitor of activator protein-1 (AP-1).(In Vitro):SR 11302 can inhibit the growth of breast cancer cell line T-47D, the lung cancer line Calu-6, and HeLa cells. SR 11302 had very little effect on either the proliferation or the differentiation of HL-60, fresh APL, and NB4 cells.(In Vivo):In an AP-1-luciferase transgenic mouse carcinogenesis model, SR11302 significantly inhibits both AP-1 activations in 7,12-dimethyl benz(a)anthracene-initiated mouse skin and 12-O-tetradecanoylphorbol-13-acetate-induced papilloma formation.
  • In Vitro
    SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα. SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells. SR 11302 (SR-11302; 2 μM; 48 hours) inhibits Helicobacter pylori (H. pylori)-induced cell proliferation in adenocarcinoma gastric (AGS) cells.SR 11302 (2 μM; 24 hours) inhibits H. pylori-induced expression of β-catenin and c-myc in AGS cells.
  • In Vivo
    SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr-/- mice in a dose-dependent manner. Animal Model:Vldlr-/- mice Dosage:Low dose 0.5 mg/kg and high dose 1 mg/kg body weight Administration:Orally gavaged daily from P5 to P15 Result:High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    11β-HSD1|Gap Junction Protein
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    160162-42-5
  • Formula Weight
    376.54
  • Molecular Formula
    C26H32O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (66.40 mM)
  • SMILES
    CC(C=CC=C(C=CC1=C(C)CCCC1(C)C)c1ccc(C)cc1)=CC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Azarashvili T, et al. Carbenoxolone induces permeability transition pore opening in rat mitochondria via the translocator protein TSPO and connexin43. Arch Biochem Biophys. 2014 Sep 15;558:87-94.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JH-RE-06

    JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.

  • Vidarabine

    Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses.

  • CCG-203971

    CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.

Sign In Join Free